PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
23444281-0	2013	Evaluation of the impact of UGT polymorphism on the pharmacokinetics and pharmacodynamics of the novel PPAR agonist sipoglitazar.	sipoglitazar	116-128	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	28-31
24214217-0	2014	A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar.	sipoglitazar	159-171	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	51-58
24214217-0	2014	A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar.	sipoglitazar	159-171	peroxisome proliferator activated receptor alpha	Homo sapiens	146-150
24214217-1	2014	The pharmacokinetics of sipoglitazar, a peroxisome proliferator activated receptor agonist, are subject to high inter-individual variability resulting from a polymorphism of the UGT2B15 genotype.	sipoglitazar	24-36	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	178-185
24214217-5	2014	The effects on FPG and HbA1c could successfully be described for placebo, rosiglitazone, and sipoglitazar treated groups in all three UGT2B15 genotypes.	sipoglitazar	93-105	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	134-141
24214217-7	2014	The current PK-PD analysis confirms that UGT2B15 genotype is a major determinant for differences in FPG and HbA1c response to sipoglitazar treatment between Type 2 Diabetes mellitus patients, due to related differences in drug exposure.	sipoglitazar	126-138	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	41-48
22960998-0	2013	The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent.	sipoglitazar	81-93	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	39-46
22960998-1	2013	PURPOSE: Sipoglitazar was a novel, azolealkanoic acid derivative that possesses selective activity for the peroxisome proliferator-activated receptors (PPAR) PPARgamma, PPARalpha, and PPARdelta.	sipoglitazar	9-21	peroxisome proliferator activated receptor alpha	Homo sapiens	107-150
22960998-1	2013	PURPOSE: Sipoglitazar was a novel, azolealkanoic acid derivative that possesses selective activity for the peroxisome proliferator-activated receptors (PPAR) PPARgamma, PPARalpha, and PPARdelta.	sipoglitazar	9-21	peroxisome proliferator activated receptor alpha	Homo sapiens	152-156
22960998-1	2013	PURPOSE: Sipoglitazar was a novel, azolealkanoic acid derivative that possesses selective activity for the peroxisome proliferator-activated receptors (PPAR) PPARgamma, PPARalpha, and PPARdelta.	sipoglitazar	9-21	peroxisome proliferator activated receptor gamma	Homo sapiens	158-167
22960998-1	2013	PURPOSE: Sipoglitazar was a novel, azolealkanoic acid derivative that possesses selective activity for the peroxisome proliferator-activated receptors (PPAR) PPARgamma, PPARalpha, and PPARdelta.	sipoglitazar	9-21	peroxisome proliferator activated receptor alpha	Homo sapiens	169-178
22960998-1	2013	PURPOSE: Sipoglitazar was a novel, azolealkanoic acid derivative that possesses selective activity for the peroxisome proliferator-activated receptors (PPAR) PPARgamma, PPARalpha, and PPARdelta.	sipoglitazar	9-21	peroxisome proliferator activated receptor delta	Homo sapiens	184-193
22960998-3	2013	The aim of this analysis was to explore the influence of genetic polymorphism in UGT on the pharmacokinetics of sipoglitazar.	sipoglitazar	112-124	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	81-84
22960998-9	2013	Subjects homozygous for the UGT2B15 D85Y variant (UGT2B15*2/*2) were exposed to greater plasma concentrations of sipoglitazar than subjects homozygous for the wild-type allele UGT2B15*1/*1 (3.26-fold higher) or heterozygous allele UGT2B15*1/*2 (2.16-fold higher).	sipoglitazar	113-125	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	28-35
22960998-9	2013	Subjects homozygous for the UGT2B15 D85Y variant (UGT2B15*2/*2) were exposed to greater plasma concentrations of sipoglitazar than subjects homozygous for the wild-type allele UGT2B15*1/*1 (3.26-fold higher) or heterozygous allele UGT2B15*1/*2 (2.16-fold higher).	sipoglitazar	113-125	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	50-57
22960998-9	2013	Subjects homozygous for the UGT2B15 D85Y variant (UGT2B15*2/*2) were exposed to greater plasma concentrations of sipoglitazar than subjects homozygous for the wild-type allele UGT2B15*1/*1 (3.26-fold higher) or heterozygous allele UGT2B15*1/*2 (2.16-fold higher).	sipoglitazar	113-125	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	50-57
22960998-9	2013	Subjects homozygous for the UGT2B15 D85Y variant (UGT2B15*2/*2) were exposed to greater plasma concentrations of sipoglitazar than subjects homozygous for the wild-type allele UGT2B15*1/*1 (3.26-fold higher) or heterozygous allele UGT2B15*1/*2 (2.16-fold higher).	sipoglitazar	113-125	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	50-57
22960998-10	2013	CONCLUSIONS: These results indicate that sipoglitazar clearance is substantially modified by UGT2B15 enzyme variants, with higher exposure observed in the UGT2B15*2/*2 genotype group.	sipoglitazar	41-53	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	93-100
22960998-10	2013	CONCLUSIONS: These results indicate that sipoglitazar clearance is substantially modified by UGT2B15 enzyme variants, with higher exposure observed in the UGT2B15*2/*2 genotype group.	sipoglitazar	41-53	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	155-162
23444281-0	2013	Evaluation of the impact of UGT polymorphism on the pharmacokinetics and pharmacodynamics of the novel PPAR agonist sipoglitazar.	sipoglitazar	116-128	peroxisome proliferator activated receptor alpha	Homo sapiens	103-107
23444281-5	2013	Model analysis demonstrated UGT2B15 genotype accounted significantly for the variability in sipoglitazar clearance; however, a small fraction of subjects had a clearance that could not be explained entirely by genotype.	sipoglitazar	92-104	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	28-35
23444281-8	2013	In summary, UGT2B15 genotype is a strong predictor for sipoglitazar clearance; a greater clinical response observed in the UGT2B15*2/*2 genotype appears to confirm this.	sipoglitazar	55-67	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	12-19
23444281-8	2013	In summary, UGT2B15 genotype is a strong predictor for sipoglitazar clearance; a greater clinical response observed in the UGT2B15*2/*2 genotype appears to confirm this.	sipoglitazar	55-67	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	123-130
22028317-8	2012	From these results, it is shown that the metabolic pathway from sipoglitazar to M-I is an unusual one, in which sipoglitazar is initially metabolized to sipoglitazar-G1 by UDP-glucuronosyltransferase and then sipoglitazar-G1 is metabolized to M-I by O-dealkylation by CYP2C8 and deconjugation.	sipoglitazar	64-76	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	268-274
23648677-1	2013	Recently, genotyping in clinical studies has revealed that UGT2B15 genetic polymorphism has an influence on the clinical pharmacokinetics of sipoglitazar.	sipoglitazar	141-153	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	59-66
23648677-3	2013	A study using UGT-expressing supersomes revealed that sipoglitazar glucuronidation was more extensively catalyzed by UGT1A1, 1A3, 1A6, 2B4, and 2B15 than by other UGTs.	sipoglitazar	54-66	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	14-17
23648677-3	2013	A study using UGT-expressing supersomes revealed that sipoglitazar glucuronidation was more extensively catalyzed by UGT1A1, 1A3, 1A6, 2B4, and 2B15 than by other UGTs.	sipoglitazar	54-66	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	117-123
23648677-5	2013	In a correlation study between sipoglitazar glucuronidation and UGT isoform-specific activities, the glucuronidation of S-oxazepam, a specific substrate for UGT2B15, strongly correlated with that of sipoglitazar, as compared with that of beta-estradiol, a representative UGT1A1 substrate.	sipoglitazar	31-43	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	64-67
23648677-5	2013	In a correlation study between sipoglitazar glucuronidation and UGT isoform-specific activities, the glucuronidation of S-oxazepam, a specific substrate for UGT2B15, strongly correlated with that of sipoglitazar, as compared with that of beta-estradiol, a representative UGT1A1 substrate.	sipoglitazar	31-43	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	157-164
23648677-5	2013	In a correlation study between sipoglitazar glucuronidation and UGT isoform-specific activities, the glucuronidation of S-oxazepam, a specific substrate for UGT2B15, strongly correlated with that of sipoglitazar, as compared with that of beta-estradiol, a representative UGT1A1 substrate.	sipoglitazar	31-43	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	271-277
23648677-5	2013	In a correlation study between sipoglitazar glucuronidation and UGT isoform-specific activities, the glucuronidation of S-oxazepam, a specific substrate for UGT2B15, strongly correlated with that of sipoglitazar, as compared with that of beta-estradiol, a representative UGT1A1 substrate.	sipoglitazar	199-211	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	64-67
23648677-5	2013	In a correlation study between sipoglitazar glucuronidation and UGT isoform-specific activities, the glucuronidation of S-oxazepam, a specific substrate for UGT2B15, strongly correlated with that of sipoglitazar, as compared with that of beta-estradiol, a representative UGT1A1 substrate.	sipoglitazar	199-211	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	157-164
23648677-5	2013	In a correlation study between sipoglitazar glucuronidation and UGT isoform-specific activities, the glucuronidation of S-oxazepam, a specific substrate for UGT2B15, strongly correlated with that of sipoglitazar, as compared with that of beta-estradiol, a representative UGT1A1 substrate.	sipoglitazar	199-211	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	271-277
23648677-7	2013	These in vitro findings indicate that UGT2B15 is principally responsible for sipoglitazar glucuronidation.	sipoglitazar	77-89	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	38-45
23648677-8	2013	Moreover, the UGT2B15*2 mutation significantly increased the Km value of sipoglitazar in the kinetic analysis using recombinant His-tag UGT2B15*1- or *2-membrane fractions.	sipoglitazar	73-85	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	14-21
23648677-8	2013	Moreover, the UGT2B15*2 mutation significantly increased the Km value of sipoglitazar in the kinetic analysis using recombinant His-tag UGT2B15*1- or *2-membrane fractions.	sipoglitazar	73-85	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	136-143
23648677-9	2013	These results show that sipoglitazar is a good example to elucidate the relationship between phenotype and genotype for UGT2B15 from in vitro analysis.	sipoglitazar	24-36	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	120-127
22123126-0	2012	Metabolic fate of sipoglitazar, a novel oral PPAR agonist with activities for PPAR-gamma, -alpha and -delta, in rats and monkeys and comparison with humans in vitro.	sipoglitazar	18-30	peroxisome proliferator activated receptor alpha	Rattus norvegicus	45-49
22123126-0	2012	Metabolic fate of sipoglitazar, a novel oral PPAR agonist with activities for PPAR-gamma, -alpha and -delta, in rats and monkeys and comparison with humans in vitro.	sipoglitazar	18-30	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	78-107
22123126-1	2012	Sipoglitazar is a novel anti-diabetic agent with triple agonistic activities on the human peroxisome proliferator-activated receptors, hPPAR-gamma, -alpha, and -delta.	sipoglitazar	0-12	peroxisome proliferator activated receptor gamma	Homo sapiens	135-166